Pasithea Therapeutics (KTTA) Other Gross PP&E Adjustments (2021 - 2026)
Pasithea Therapeutics recorded quarterly Other Gross PP&E Adjustments of -$472623.0 in Q1 2026, down 36.99% quarter-over-quarter from -$345000.0 in Q4 2025, and down 51.91% year-over-year from -$982792.5 in Q1 2025.
Pasithea Therapeutics' Other Gross PP&E Adjustments history runs 6 years deep, the most recent figure standing at -$472623.0 for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments fell 51.91% year-over-year to -$472623.0; the TTM figure through Mar 2026 stood at -$975164.0 (down 213.44% YoY), while the FY2025 annual figure was -$345000.0, down 142.44% from the prior year.
- Other Gross PP&E Adjustments came in at -$472623.0 for Q1 2026 at Pasithea Therapeutics, down from -$345000.0 in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $7155.0 in Q3 2024 to a low of -$184.2 million in Q1 2023.
- A 5-year average of -$11.8 million and a median of -$344787.5 in 2023 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments jumped 101.93% in 2024 and slumped 2301.83% in 2025, its largest moves.
- Pasithea Therapeutics' Other Gross PP&E Adjustments stood at -$387372.0 in 2022, then increased by 11.05% to -$344575.0 in 2023, then soared by 58.7% to -$142304.0 in 2024, then sank by 142.44% to -$345000.0 in 2025, then tumbled by 36.99% to -$472623.0 in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$472623.0, -$345000.0, and -$157541.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | -472,623.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -472,623.00 |
| Mar 31, 2026 | -472,623.00 |
| Dec 31, 2025 | -345,000.00 |
| Dec 31, 2025 | -345,000.00 |
| Sep 30, 2025 | -157,541.00 |
| Sep 30, 2025 | -157,541.00 |
| Jun 30, 2025 | -153,579.00 |
| Jun 30, 2025 | -153,579.00 |
| Mar 31, 2025 | -311,120.00 |
| Mar 31, 2025 | -311,120.00 |
| Dec 31, 2024 | -142,304.00 |
| Dec 31, 2024 | -142,304.00 |
| Sep 30, 2024 | 7,155.00 |
| Sep 30, 2024 | 7,155.00 |
| Jun 30, 2024 | -150,386.00 |
| Jun 30, 2024 | -150,386.00 |
| Mar 31, 2024 | -339,953.00 |
| Mar 31, 2024 | -339,953.00 |
| Dec 31, 2023 | -344,575.00 |
| Dec 31, 2023 | -344,575.00 |
| Sep 30, 2023 | -371,298.00 |
| Sep 30, 2023 | -371,298.00 |
| Jun 30, 2023 | -419,885.00 |
| Jun 30, 2023 | -419,885.00 |
| Mar 31, 2023 | -184.25 Mn |
| Mar 31, 2023 | -184.25 Mn |
| Dec 31, 2022 | -387,372.00 |
| Dec 31, 2022 | -387,372.00 |
| Sep 30, 2022 | -931,964.00 |
| Sep 30, 2022 | -931,964.00 |
| Jun 30, 2022 | -410,392.00 |
| Jun 30, 2022 | -410,392.00 |
| Dec 31, 2021 | -21.50 Mn |
| Dec 31, 2021 | -21.50 Mn |